Top of this page
Skip navigation, go straight to the content
Our Science
•
Pipeline
PIPELINE
Our pipeline builds the basis of UCB’s future, so our focus is on breakthrough innovative approaches with the goal of developing new highly differentiated solutions that will significantly impact the lives of patients. We have developed unique partnerships with patients at every step of the clinical development process to identify needs and inform study design and operations.
| Indications | Phase 1 | Phase 2 | Phase 3 | Filing | ||
|---|---|---|---|---|---|---|
| bimekizumab (IL17AF) | psoriasis |  | ||||
| psoriatic arthritis |  | |||||
| axial spondyloarthritis | | |||||
| hidradenitis suppurativa | | |||||
| zilucoplan (C5) | myasthenia gravis | | ||||
| rozanolixizumab (FcRn) | myasthenia gravis | | ||||
| immune thrombocytopenia | | |||||
| MOG-antibody disease |  | |||||
| autoimmune encephalitis |  | |||||
| dapirolizumab pegol (CD40L) | systemic lupus erythematosus1 | | ||||
| Staccato® alprazolam | active epileptic seizure | | ||||
| bepranemab (anti-tau antibody) | Alzheimer's disease2 |  | ||||
| UCB0599 (α-syn-misfolding inhibitor) | Parkinson's disease | | ||||
| 5 Projects |  | |||||
1 In partnership with Biogen 2 In partnership with Roche/Genentech
Zilucoplan in amyotrophic lateral sclerosis (ALS) by HEALEY ALS Platform Trial MOG: myelin oligodendrocyte glycoprotein-antibody disease |